---
title: 'Senior Manager / Associate Director, Publications and Medical Information (Contract) at Nurix'
canonical: 'https://feeny.ai/job/senior-manager-associate-director-publications-and-medical-information-contract-g2syp7xqhxr4'
type: 'job'
last_seen: '2026-10-29'
---

# Senior Manager / Associate Director, Publications and Medical Information (Contract) at Nurix

- **Company:** Nurix
- **Location:** Brisbane, CA
- **Posted:** 2026-09-18
- **Last confirmed live:** 2026-10-29
- **Apply:** https://job-boards.greenhouse.io/nurix/jobs/8821613002

## Job description

Senior Manager / Associate Director, Publications and Medical Information (Contract)

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease.

Job Responsitities:

Publications

- Contribute to development of Publication Strategy and Publication Plan (in coordination with the Publications Working Team)
- Execute publication tactics and the Publication Plan
- Manage the drafting process for clinical publications (with vendor/agency), tracking timelines and ensuring timely reviews, approvals, and submissions
- Interact with internal and external authors/KOLs related to clinical publications
- Manage record keeping and digital storage for publications-related materials, including publications metrics

Data Reviews

- Contribute to development of data review slide decks and derivative materials (with vendor/agency)
- Support data presentation-related AI projects

Congress Support

- Support booth staffing, congress materials, and presentation logistics (in coordination with Medical Affairs Operations)
- Provide dedicated congress/booth Medical Information support

Medical Information

- Draft Standard Response Letters and manage related Medical and Legal review
- Ensure timely responses to medical inquiries; coordinate with the Medical Information team at a partner company and track inquiry volumes
- Create FAQs and reference materials (in coordination with internal Subject Matter Experts)
- Support Medical Information-related AI projects

Education:

- Doctoral degree in a medical, biological, or related discipline (PhD, PharmD, MD; MS with relevant experience considered)

Experience:

- 3-4 years of experience (Sr. Manager) or 4-5 years of experience (Associate Director) in Medical Affairs, Medical Communications, Clinical Publications, or Medical Information
- Demonstrated experience managing scientific/clinical publications end-to-end
- Familiarity with publication management and MLR processes/procedures
- Experience with medical information operations and Standard Response Letter (SRL) development

Skills:

- Strong working knowledge of GPP, ICMJE, and industry compliance requirements
- Excellent scientific writing, editing, and critical literature-review skills
- Excellent communication skills
- Project management and time management skills, with the ability to operate within multiple concurrent timelines
- Cross-functional collaboration skills, with the ability to align with internal teams of Subject Matter Experts representing different functions

Fit with Nurix Culture and Values

- Strong team orientation; highly collaborative
- Solutions and results-oriented focus
- Hands-on approach; resourceful and open to diverse points of view

Location:          Brisbane, CA - Onsite

## About Nurix

## Company Overview
- **One-liner**: Nurix Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation medicines to outmatch disease by harnessing the cell’s natural protein disposal system.
- **Entity Type**: Public (NASDAQ: NRIX)
- **Headquarters**: San Francisco, California, USA
- **Founded**: 2009
- **Founders**: Not publicly listed as individual founders; the company was spun out from research at UC Berkeley and UC San Francisco.

## Core Business
- **Primary industry**: Biopharmaceuticals / Targeted Protein Degradation
- **Target customers**: B2B (pharma partners) and B2C (patients via clinical trials and eventual commercial therapies); enterprise-level partnerships with major pharma.
- **Mission or purpose statement**: "Writing medicine’s next chapter using targeted protein degradation as a new script to outmatch disease." [nurixtx.com](https://www.nurixtx.com/)

## Products & Services
- **Bexobrutideg (NX-5948)**: A potential best-in-class BTK degrader in Phase 1b/2 clinical trials for relapsed/refractory CLL/SLL and chronic spontaneous urticaria. Co-developed and co-commercialized with Roche under a global collaboration announced June 2026. [nurixtx.com](https://www.nurixtx.com/)
- **NX-2127**: A BTK degrader in clinical development for B-cell malignancies.
- **CBL-B Inhibitor (NX-1607)**: An E3 ligase inhibitor designed to activate T cells for immuno-oncology, in Phase 1 clinical trials.
- **IRAK4 Degrader**: A partnered program with Gilead in Phase 1 for inflammatory diseases.
- **STAT6 Degrader**: A partnered program with Sanofi in IND-enabling studies.
- **DEL-AI Discovery Engine**: A proprietary, fully AI-integrated platform combining DNA-encoded libraries (DEL), automated chemistry, and machine learning to design and optimize targeted protein degraders and degrader-antibody conjugates (DACs).

## Market Standing
- **Valuation/Market Cap**: Not publicly available in the provided search results; as a public company (NRIX), market cap fluctuates daily. Check financial platforms for the latest figure.
- **Key Metric**: Annual Revenue (public) — Not publicly available in the provided search results; as a clinical-stage biotech, revenue is typically minimal or pre-revenue. Total funding raised prior to IPO is not detailed in the provided results.
- **Notable Investors/Partners**: Roche (global co-development and co-commercialization collaboration for bexobrutideg, announced June 2026), Gilead (partnered IRAK4 degrader program), Sanofi (partnered STAT6 degrader program).
- **Growth Signals**: Announced a landmark global collaboration with Roche in June 2026 to co-develop and co-commercialize bexobrutideg across malignant hematology, immunology, and neurology. Presented positive Phase 1a/b data for bexobrutideg in CLL/SLL and chronic spontaneous urticaria in 2026. Multiple partnered and wholly owned pipeline programs advancing through clinical and preclinical stages.

## Competitive Advantages
- **Proprietary DEL-AI Discovery Engine**: A fully AI-integrated platform combining DNA-encoded libraries, automated chemistry, and machine learning to design degraders against any protein class, providing a significant speed and innovation advantage. [nurixtx.com](https://www.nurixtx.com/)
- **Unparalleled Ligase Expertise**: Deep understanding of E3 ligase biochemistry and biology, a critical and complex component of the protein degradation mechanism, giving them a unique moat.
- **Multi-Modal Pipeline**: Developing both small molecule degraders and Degrader-Antibody Conjugates (DACs), expanding the therapeutic reach and creating multiple shots on goal.
- **Strong Partnership Network**: Collaborations with top-tier pharma (Roche, Gilead, Sanofi) validate their platform and provide non-dilutive funding and shared risk.

## Strategic Focus
- **Clinical Advancement**: Driving lead asset bexobrutideg through pivotal trials in CLL/SLL and expanding into immunology (chronic spontaneous urticaria) and neurology.
- **Platform Expansion**: Leveraging the DEL-AI engine to develop Degrader-Antibody Conjugates (DACs) for enhanced cell specificity and safety.
- **Pipeline Breadth**: Advancing a multi-modal pipeline across oncology, immunology, and neurology, both wholly owned and through strategic partnerships.
- **Partnership Leverage**: Deepening collaborations with Roche, Gilead, and Sanofi to co-develop and co-commercialize programs, reducing risk and accelerating timelines.

## Why Work Here
- **Culture**: Mission-focused, values-based, and spirited culture emphasizing "breakthrough innovation," "leadership," "accountability," and "zealousness." Employees are encouraged to "think big and act bold." [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
- **Work with Industry Leaders**: The team includes scientific innovators who built the protein degradation field, seasoned executives with biotech scaling expertise, and leading clinicians. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
- **Growth & Impact**: Employees can "wear many hats" and gain broad exposure in a lean, virtual drug developer environment. The company emphasizes career growth and opportunity-rich experiences.
- **Work Policy**: Onsite in Brisbane, CA (San Francisco Bay Area) for most roles, as indicated by job postings. [nurixtx.com](https://www.nurixtx.com/explore-jobs/)
- **Benefits**: Comprehensive health and welfare plans, enhanced parental leave, wellness reimbursement, 401(k) employer match, and a highly collaborative culture. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
- **Engineering/Science Culture**: Described as "mission-focused, values-based, and spirited," with a focus on "intellectual and technical ingenuity" and "intelligent risk-taking." The company is a "virtual drug developer" with a lean internal infrastructure, relying on SaaS and cloud platforms. [nurixtx.com](https://www.nurixtx.com/explore-jobs/)

## Sources
1. [nurixtx.com](https://www.nurixtx.com/)
2. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
3. [nurixtx.com](https://www.nurixtx.com/explore-jobs/)
4. [nurixtx.com](https://www.nurixtx.com/our-story/)

## Other roles at Nurix

- [Director, Quality Assurance](https://feeny.ai/job/director-quality-assurance-nurix-brisbane-3g1nz641gtdv) — Brisbane, CA
- [Senior/Principal Scientist, Medicinal Chemistry](https://feeny.ai/job/senior-principal-scientist-medicinal-chemistry-nurix-brisbane-sk240f67bwms) — Brisbane, CA
- [Scientist I, Bioanalytical](https://feeny.ai/job/scientist-i-bioanalytical-nurix-brisbane-tns4szvd5c07) — Brisbane, CA
- [Senior Research Associate, Preclinical Pharmacology](https://feeny.ai/job/senior-research-associate-preclinical-pharmacology-nurix-brisbane-whtmqmhser7g) — Brisbane, CA
- [Senior Scientist, Medicinal Chemistry](https://feeny.ai/job/senior-scientist-medicinal-chemistry-nurix-the-woodlands-y4nmgjxktsm5) — The Woodlands, TX
- [Scientist I, Medicinal Chemistry](https://feeny.ai/job/scientist-i-medicinal-chemistry-nurix-the-woodlands-bxgy2c1m60vz) — The Woodlands, TX
- [Senior Director, Head of Pharmacovigilance Operations](https://feeny.ai/job/senior-director-head-of-pharmacovigilance-operations-nurix-brisbane-qvx5sf5gc0cv) — Brisbane, CA
- [Senior Manager / Associate Director, Regulatory Affairs CMC (Small Molecules)](https://feeny.ai/job/senior-manager-associate-director-regulatory-affairs-cmc-small-molecules-nurix-pp3fh8jc68k1) — Brisbane, CA
- [Administrative Assistant, Clinical Development (Contract)](https://feeny.ai/job/administrative-assistant-clinical-development-contract-nurix-brisbane-6rnsp2fj2vte) — Brisbane, CA
- [Administrative Assistant, CMC (Contract)](https://feeny.ai/job/administrative-assistant-cmc-contract-nurix-brisbane-cgkssyzb35sq) — Brisbane, CA